Recordati_rare_diseases_inc.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$2.8Mgeneral payments (2019-2025)
$2.0Mresearch payments (2019-2025)
8,464clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Isturisa $966K associated (2023-2025)
- Sylvant $494K associated (2023-2025)
- Panhematin $193K associated (2023-2025)
- Enjaymo $177K associated (2023-2025)
- Osilodrostat $158K associated (2023-2025)
- Signifor Lar $150K associated (2023-2025)
- Cystadrops $35K associated (2023-2025)
- Siltuximab $7,632 associated (2023-2025)
- Carbaglu $829 associated (2023-2025)
- Cystadane $373 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Elena Christofides | Columbus, OH | Endocrinology, Diabetes & Metabolism | $155,447.07 |
| Wenyu Huang | Chicago, IL | Endocrinology, Diabetes & Metabolism | $107,946.50 |
| Maria Fleseriu | Portland, OR | Endocrinology, Diabetes & Metabolism | $97,189.66 |
| Nicholas Ah Mew | Washington, DC | Clinical Genetics (M.D.) | $80,000.00 |
| Corey Casper | Seattle, WA | Infectious Disease | $73,308.87 |
| Anthony Heaney | Los Angeles, CA | Endocrinology, Diabetes & Metabolism | $69,295.92 |
| Catherine Broome | Washington, DC | Hematology & Oncology | $63,468.07 |
| Atil Kargi | Chapel Hill, NC | Endocrinology, Diabetes & Metabolism | $53,335.86 |
| Beverly Biller | Boston, MA | Endocrinology, Diabetes & Metabolism | $50,680.36 |
| Frits Van Rhee | Little Rock, AR | Hematology & Oncology | $48,096.00 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.